Experts at Elevate examined the evolving role of psychedelics in mental health care, highlighting emerging research, clinical considerations, and questions around access and safety.
Experts at Elevate examined the evolving role of psychedelics in mental health care, highlighting emerging research, clinical considerations, and questions around access and safety.
A single dose of psilocybin was associated with a significant reduction in depressive symptoms within 2 days of administration in patients with major depressive disorder (MDD), according to randomized control trial results.
A single dose of psilocybin was associated with a significant reduction in depressive symptoms within 2 days of administration in patients with major depressive disorder (MDD), according to randomized control trial results.
Steering Committee members Charles Raison, MD, and Andrew Penn, MS, PMHNP-BC, discuss why recent regulatory actions could mark an inflection point for psychedelic psychiatry.
Steering Committee members Charles Raison, MD, and Andrew Penn, MS, PMHNP-BC, discuss why recent regulatory actions could mark an inflection point for psychedelic psychiatry.
Following an April 18 executive order, the US Food and Drug Administration (FDA) announced new regulatory actions to accelerate the development of psychedelic-assisted therapy for mental health conditions.
Following an April 18 executive order, the US Food and Drug Administration (FDA) announced new regulatory actions to accelerate the development of psychedelic-assisted therapy for mental health conditions.
President Donald J. Trump signed an executive order titled “Accelerating Medical Treatments for Serious Mental Illness,” which aims to expand psychedelic therapy access for significant mental health issues, such as suicidality, major...
President Donald J. Trump signed an executive order titled “Accelerating Medical Treatments for Serious Mental Illness,” which aims to expand psychedelic therapy access for significant mental health issues, such as suicidality, major...
A Phase 2b randomized clinical trial found nonsignificant differences in response rate between psilocybin 25 mg, psilocybin 5 mg, and placebo with supporting psychotherapy in treatment-resistant major depressive disorder (MDD).
A Phase 2b randomized clinical trial found nonsignificant differences in response rate between psilocybin 25 mg, psilocybin 5 mg, and placebo with supporting psychotherapy in treatment-resistant major depressive disorder (MDD).
A phase 2b randomized clinical trial found that inhaled GH001, a synthetic formulation of mebufotenin, produced rapid antidepressant effects in adults with treatment-resistant depression (TRD).
A phase 2b randomized clinical trial found that inhaled GH001, a synthetic formulation of mebufotenin, produced rapid antidepressant effects in adults with treatment-resistant depression (TRD).
A synthetic form of psilocybin (COMP360) has met the primary endpoint in a second phase 3 trial evaluating its efficacy and safety in patients with treatment-resistant depression (TRD).
A synthetic form of psilocybin (COMP360) has met the primary endpoint in a second phase 3 trial evaluating its efficacy and safety in patients with treatment-resistant depression (TRD).
A systematic review and meta-analysis of 7 clinical trials and 4 published protocol papers found that nitrous oxide (N2O) may offer rapid-acting benefit for the treatment of depression.
A systematic review and meta-analysis of 7 clinical trials and 4 published protocol papers found that nitrous oxide (N2O) may offer rapid-acting benefit for the treatment of depression.
Psychedelics could be a promising treatment option for patients with opioid use disorder (OUD), according to a recent systematic review of preclinical animal studies published in Cellular and Molecular Life Sciences.
Psychedelics could be a promising treatment option for patients with opioid use disorder (OUD), according to a recent systematic review of preclinical animal studies published in Cellular and Molecular Life Sciences.
A single dose of psilocybin was associated with a significant reduction in depressive symptoms within 2 days of administration in patients with major depressive disorder (MDD), according to randomized control trial results.
A single dose of psilocybin was associated with a significant reduction in depressive symptoms within 2 days of administration in patients with major depressive disorder (MDD), according to randomized control trial results.
President Donald J. Trump signed an executive order titled “Accelerating Medical Treatments for Serious Mental Illness,” which aims to expand psychedelic therapy access for significant mental health issues, such as suicidality, major...
President Donald J. Trump signed an executive order titled “Accelerating Medical Treatments for Serious Mental Illness,” which aims to expand psychedelic therapy access for significant mental health issues, such as suicidality, major...
A Phase 2b randomized clinical trial found nonsignificant differences in response rate between psilocybin 25 mg, psilocybin 5 mg, and placebo with supporting psychotherapy in treatment-resistant major depressive disorder (MDD).
A Phase 2b randomized clinical trial found nonsignificant differences in response rate between psilocybin 25 mg, psilocybin 5 mg, and placebo with supporting psychotherapy in treatment-resistant major depressive disorder (MDD).
A phase 2b randomized clinical trial found that inhaled GH001, a synthetic formulation of mebufotenin, produced rapid antidepressant effects in adults with treatment-resistant depression (TRD).
A phase 2b randomized clinical trial found that inhaled GH001, a synthetic formulation of mebufotenin, produced rapid antidepressant effects in adults with treatment-resistant depression (TRD).
A synthetic form of psilocybin (COMP360) has met the primary endpoint in a second phase 3 trial evaluating its efficacy and safety in patients with treatment-resistant depression (TRD).
A synthetic form of psilocybin (COMP360) has met the primary endpoint in a second phase 3 trial evaluating its efficacy and safety in patients with treatment-resistant depression (TRD).
Psychedelics could be a promising treatment option for patients with opioid use disorder (OUD), according to a recent systematic review of preclinical animal studies published in Cellular and Molecular Life Sciences.
Psychedelics could be a promising treatment option for patients with opioid use disorder (OUD), according to a recent systematic review of preclinical animal studies published in Cellular and Molecular Life Sciences.
The US Food and Drug Administration (FDA) last week rejected the new drug application (NDA) from Lykos Therapeutics for midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD) in conjunction with...
The US Food and Drug Administration (FDA) last week rejected the new drug application (NDA) from Lykos Therapeutics for midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD) in conjunction with...
Ketamine was associated with greater treatment response than electroconvulsive therapy in patients with nonpsychotic treatment-resistant depression who had moderately severe or severe pretreatment symptoms and who initiated treatment as...
Ketamine was associated with greater treatment response than electroconvulsive therapy in patients with nonpsychotic treatment-resistant depression who had moderately severe or severe pretreatment symptoms and who initiated treatment as...
FDA committee rejected an MDMA-based therapy for adult PTSD treatment due to concerns about its effectiveness and the reliability of the data, despite positive study results.
FDA committee rejected an MDMA-based therapy for adult PTSD treatment due to concerns about its effectiveness and the reliability of the data, despite positive study results.
To address the challenges and “inadequate outcomes” with monoamine-based therapies, a Toronto-based research team investigated novel alternatives for TRD.
To address the challenges and “inadequate outcomes” with monoamine-based therapies, a Toronto-based research team investigated novel alternatives for TRD.
A 3-year longitudinal study found that insomnia, excessive daytime sleepiness (EDS), and their co-occurrence were associated with increased risk of depression.
A 3-year longitudinal study found that insomnia, excessive daytime sleepiness (EDS), and their co-occurrence were associated with increased risk of depression.
Navacaprant, a kappa opioid receptor antagonist for major depressive disorder treatment, failed to show statistically significant efficacy in two phase 3 trials.
Navacaprant, a kappa opioid receptor antagonist for major depressive disorder treatment, failed to show statistically significant efficacy in two phase 3 trials.
Evaluating reduced stimulant use rather than complete abstinence outcomes in patients with stimulant use disorder could provide additional insight into treatment efficacy.
Evaluating reduced stimulant use rather than complete abstinence outcomes in patients with stimulant use disorder could provide additional insight into treatment efficacy.
New research further characterizes viloxazine’s pharmacologic profile, supporting a multimodal mechanism involving norepinephrine transporters and serotonin receptors.
New research further characterizes viloxazine’s pharmacologic profile, supporting a multimodal mechanism involving norepinephrine transporters and serotonin receptors.
A retrospective cohort study examined the association between pediatric ADHD, methylphenidate exposure, and adult BMI and height outcomes. The findings suggest that ADHD—particularly when treated with methylphenidate—may be associated with...
A retrospective cohort study examined the association between pediatric ADHD, methylphenidate exposure, and adult BMI and height outcomes. The findings suggest that ADHD—particularly when treated with methylphenidate—may be associated with...
A single dose of psilocybin was associated with a significant reduction in depressive symptoms within 2 days of administration in patients with major depressive disorder (MDD), according to randomized control trial results.
A single dose of psilocybin was associated with a significant reduction in depressive symptoms within 2 days of administration in patients with major depressive disorder (MDD), according to randomized control trial results.
Once-monthly aripiprazole 400 mg (AOM 400) demonstrated a favorable risk-benefit profile as an acute and long-term maintenance treatment in patients with schizophrenia.
Once-monthly aripiprazole 400 mg (AOM 400) demonstrated a favorable risk-benefit profile as an acute and long-term maintenance treatment in patients with schizophrenia.
A new systematic review and network meta-analysis published in JAMA Psychiatry evaluated the comparative efficacy and acceptability of the 5 FDA-approved atypical antipsychotics used as adjunctive therapy for major depressive disorder (MDD).
A new systematic review and network meta-analysis published in JAMA Psychiatry evaluated the comparative efficacy and acceptability of the 5 FDA-approved atypical antipsychotics used as adjunctive therapy for major depressive disorder (MDD).
A report published by CDC in August 2020 showed huge increases in mental health issues during the time period April-June 2020 compared with the same time period the previous year. Instances of suicidal conditions increased 200%, anxiety...
A report published by CDC in August 2020 showed huge increases in mental health issues during the time period April-June 2020 compared with the same time period the previous year. Instances of suicidal conditions increased 200%, anxiety...
BLOG: In a recent study, the utilization of psychedelic medicine in group therapy was linked with reduced demoralization among long-term, gay-identified, male HIV survivors—an outcome with larger implications for overall healthcare.
BLOG: In a recent study, the utilization of psychedelic medicine in group therapy was linked with reduced demoralization among long-term, gay-identified, male HIV survivors—an outcome with larger implications for overall healthcare.
BLOG: Psychedelic-assisted therapies, once consigned to the fringes of psychiatric practice, are exploding into the mainstream of psychiatry and will take center stage at a Psych Congress preconference.
BLOG: Psychedelic-assisted therapies, once consigned to the fringes of psychiatric practice, are exploding into the mainstream of psychiatry and will take center stage at a Psych Congress preconference.
BLOG: Michael Pollan, author of The Omnivore’s Dilemma and The Botany of Desire, has turned his spotlight of curiosity onto the subject of psychedelics with his new book How to Change Your Mind.
BLOG: Michael Pollan, author of The Omnivore’s Dilemma and The Botany of Desire, has turned his spotlight of curiosity onto the subject of psychedelics with his new book How to Change Your Mind.
BLOG: Recent qualitative studies on subjects treated with psilocybin may begin to help us understand the subjective experience caused by the drug that may lead to its antidepressant effects.
BLOG: Recent qualitative studies on subjects treated with psilocybin may begin to help us understand the subjective experience caused by the drug that may lead to its antidepressant effects.
BLOG: These studies were the latest findings showing that psychedelics, erroneously dismissed as mere intoxicants and swept up in the hysteria of the Nixon-era drug wars, could prove to be as important to psychiatry as penicillin was to...
BLOG: These studies were the latest findings showing that psychedelics, erroneously dismissed as mere intoxicants and swept up in the hysteria of the Nixon-era drug wars, could prove to be as important to psychiatry as penicillin was to...
Psychedelic compounds are powerful, and they have great potential to help patients with intractable conditions. Yet any compound with that kind of power also has the potential to harm, and that harm should not be trivialized.
Psychedelic compounds are powerful, and they have great potential to help patients with intractable conditions. Yet any compound with that kind of power also has the potential to harm, and that harm should not be trivialized.
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
Rakesh Amin, MD, discusses the importance of partnering with patients and caregivers to set treatment goals and the importance of introducing long-acting injectables earlier in the treatment of schizophrenia.
Rakesh Amin, MD, discusses the importance of partnering with patients and caregivers to set treatment goals and the importance of introducing long-acting injectables earlier in the treatment of schizophrenia.
Psych Congress Network Section Editor Mark Agronin, MD, provides expert clinical insights on reducing the risk for Alzheimer disease and delaying its onset and progression.
Psych Congress Network Section Editor Mark Agronin, MD, provides expert clinical insights on reducing the risk for Alzheimer disease and delaying its onset and progression.
Ed Jones, PhD, discusses the need for a clinical refocusing that includes broad access to psychosocial solutions and ensuring socially informed clinicians can help underserved communities.
Ed Jones, PhD, discusses the need for a clinical refocusing that includes broad access to psychosocial solutions and ensuring socially informed clinicians can help underserved communities.
Ed Jones, PhD: "We miss this psychosocial aspect of care today...What is missing? We need psychotherapists based in primary care, often focused on mundane issues rather than the complexities of diagnosis or treatment."
Ed Jones, PhD: "We miss this psychosocial aspect of care today...What is missing? We need psychotherapists based in primary care, often focused on mundane issues rather than the complexities of diagnosis or treatment."
Andrew Penn, NP, explains mentoring, how to find one as an NP, and what to do when you have found a possible mentor. He gives practical advice, questions to ask, and avenues to find the right fit.
Andrew Penn, NP, explains mentoring, how to find one as an NP, and what to do when you have found a possible mentor. He gives practical advice, questions to ask, and avenues to find the right fit.
In this blog, Julie Bailey, LCPC, shares her insights on providing a safe space for patients to discuss these social anxieties, as well as tips to share with patients about slowly reintegrating into life after COVID-19.
In this blog, Julie Bailey, LCPC, shares her insights on providing a safe space for patients to discuss these social anxieties, as well as tips to share with patients about slowly reintegrating into life after COVID-19.
The US Food and Drug Administration (FDA) recently gave the Breakthrough Therapy designation to psilocybin for the treatment of which mental health condition?
The US Food and Drug Administration (FDA) recently gave the Breakthrough Therapy designation to psilocybin for the treatment of which mental health condition?
How well do you understand the relationship between pediatric attention-deficit/hyperactivity disorder, methylphenidate use in childhood, and growth outcomes in adulthood? Test your knowledge with this short, multiple-choice quiz.
How well do you understand the relationship between pediatric attention-deficit/hyperactivity disorder, methylphenidate use in childhood, and growth outcomes in adulthood? Test your knowledge with this short, multiple-choice quiz.
Why does Desiree Matthews, PMHNP-BC, recommend careful consideration of metabolic pathways when selecting a vesicular monoamine transporter 2 (VMAT2) inhibitor for tardive dyskinesia (TD) treatment?
Why does Desiree Matthews, PMHNP-BC, recommend careful consideration of metabolic pathways when selecting a vesicular monoamine transporter 2 (VMAT2) inhibitor for tardive dyskinesia (TD) treatment?
Why does Desiree Matthews, PMHNP-BC, recommend careful consideration of metabolic pathways when selecting a vesicular monoamine transporter 2 (VMAT2) inhibitor for tardive dyskinesia (TD) treatment?
Why does Desiree Matthews, PMHNP-BC, recommend careful consideration of metabolic pathways when selecting a vesicular monoamine transporter 2 (VMAT2) inhibitor for tardive dyskinesia (TD) treatment?
Differences in ADHD presentation between males and females may affect diagnosis and outcomes. Evaluate your understanding of key clinical distinctions with this short quiz.
Differences in ADHD presentation between males and females may affect diagnosis and outcomes. Evaluate your understanding of key clinical distinctions with this short quiz.
What is the recommended first step to confirm whether a patient is experiencing excessive daytime sleepiness? Take this quick quiz to test your knowledge!
What is the recommended first step to confirm whether a patient is experiencing excessive daytime sleepiness? Take this quick quiz to test your knowledge!
Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN
Featuring Andrew Penn, MS, PMHNP...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
